How close are we to ending Alzheimer's?

The Wall Street Journal reporter, who is the first US journalist charged with spying in Russia since the Cold War, has now been imprisoned for a year. His detention has been repeatedly extended and he is yet to face trial. His family, colleagues and the US government vehemently d ...  Show more

Over the past year thousands of journalists have lost their jobs as mass media news organisations struggle to make ends meet. Ad revenue is down, many publishers are struggling to gain subscribers, and social media has resulted in plummeting traffic to homepages. More than a thir ...  Show more

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ...  Show more

A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ...  Show more

Until recently, breakthroughs in treating Alzheimer’s disease were non-existent. But two new drugs have shown promise in moderately slowing memory and thinking problems for people with early-stage disease. While welcoming the idea of a ‘new era’ for treating Alzheimer’s disease, ...  Show more